Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach